DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

Information source: Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hepatitis C, Chronic

Intervention: Telaprevir (Drug); Pegylated Interferon Alfa-2a (Drug); Ribavirin (Drug)

Phase: Phase 3

Status: Terminated

Sponsored by: Vertex Pharmaceuticals Incorporated

Official(s) and/or principal investigator(s):
Mark Friedman, M.D., Study Director, Affiliation: Vertex Pharmaceuticals Incorporated

Summary

The purpose of this study is to evaluate if a 12-week total regimen of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) (T12/PR12) is safe and effective in subjects who have the interleukin-28B (IL28B) CC genotype. The subjects enrolled in this study will have chronic hepatitis C virus (HCV) infection and will not have cirrhosis of the liver.

Clinical Details

Official title: A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (PegasysŪ), and Ribavirin (CopegusŪ) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Genotype

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Percentage of Subjects With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)

Secondary outcome:

Percentage of Subjects With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)

Percentage of Subjects With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)

Percentage of Subjects With Sustained Viral Response at Week 72 (SVR72)

Percentage of Subjects With Viral Relapse

Percentage of Subjects With On-Treatment Virologic Failure

Number of Subjects With Rapid Viral Response (RVR)

Number of Subjects With Extended Rapid Viral Response (eRVR)

Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Eligibility

Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male and female subjects, 18 to 70 years of age, inclusive

- Treatment-naive OR subjects (prior relapsers) may be included who did not achieve

sustained viral response 24 weeks after last planned dose of study drug (SVR24) after at least 1 prior course of Peg-IFN/RBV therapy of standard duration and had a documented undetectable HCV RNA level at the planned end of treatment of at least 42-week duration

- Subjects have IL28B CC genotype determined during screening

- Subjects have genotype 1 chronic hepatitis C and laboratory evidence of HCV infection

for at least 6 months, defined by (1) documented HCV serology test at least 6 months before the first screening visit demonstrating the presence of anti-HCV antibody, or (2) documented presence of HCV RNA by a sensitive and specific assay at least 6 months before the first screening visit, or (3) documented histologic evidence of chronic hepatitis C demonstrated by fibrosis on a standardized histologic grading system at least 6 months before the first screening visit. If only inflammation is present in the liver histologic report, then 6 months of laboratory evidence is required Exclusion Criteria:

- Subjects have received previous treatment with telaprevir or any other protease

inhibitor(s) for chronic hepatitis C

- Subjects who did not achieve SVR24 after at least 1 prior course of Peg-IFN/RBV

therapy of standard duration and never achieved undetectable HCV RNA while on treatment

- Subjects have evidence of hepatic decompensation

- Subjects have evidence of cirrhosis

- Subjects have diagnosed or suspected hepatocellular carcinoma

- Subjects have any other cause of significant liver disease in addition to hepatitis

C, which may include but is not limited to malignancy with hepatic involvement, hepatitis B, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, nonalcoholic steatohepatitis, or primary biliary cirrhosis. Steatosis is allowed if clinically asymptomatic

Locations and Contacts

Linz 4010, Austria

Vienna 1090, Austria

Vienna 1160, Austria

Berlin 10969, Germany

Dusseldorf 40237, Germany

Frankfurt 60590, Germany

Hamburg 20099, Germany

Hannover 30625, Germany

Koeln 50937, Germany

Leipzig 4103, Germany

Munich 81377, Germany

Haifa 31096, Israel

Haifa 34362, Israel

Israel, Jerusalem 91120, Israel

Nazareth 16100, Israel

Petah Tikva 49100, Israel

Tel Hashomer 52621, Israel

Bialystok 16-540, Poland

Czeladz 41-250, Poland

Myslowice 41-400, Poland

Wroclaw 50-220, Poland

Birmingham, Alabama 35209, United States

Birmingham, Alabama 35294, United States

Calgary, Alberta T2N 4Z6, Canada

Edmonton, Alberta T5M 1J7, Canada

Edmonton, Alberta T6G 2X8, Canada

Phoenix, Arizona 85054, United States

Vancouver, British Columbia V6T 1Z3, Canada

La Jolla, California 93037, United States

Los Angeles, California 90027, United States

California, Los Angeles, California 90048, United States

Sacramento, California 95817, United States

San Diego, California 92103, United States

San Diego, California 92105, United States

San Diego, California 92154, United States

California, San Francisco, California 94115, United States

Farmington, Connecticut 06030, United States

New Haven, Connecticut 06511, United States

Bradenton, Florida 34209, United States

Gainesville, Florida 32224, United States

Jacksonville, Florida 32224, United States

Jacksonville, Florida 32256, United States

Orlando, Florida 32803, United States

Atlanta, Georgia 30308, United States

Marietta, Georgia 30060, United States

Honolulu, Hawaii 96817, United States

Chicago, Illinois 60612, United States

Chicago, Illinois 60611, United States

Winnipeg, Manitoba R3E 3P4, Canada

Baltimore, Maryland 21202, United States

Baltimore, Maryland 21287, United States

Columbia, Maryland 21045, United States

Boston, Massachusetts 02215, United States

Brockton, Massachusetts 02302, United States

Burlington, Massachusetts 01805, United States

Worcester, Massachusetts 01605, United States

Novi, Michigan 48202, United States

Kansas City, Missouri 64131, United States

Lebanon, New Hampshire 03756, United States

Egg Harbor Township, New Jersey 08234, United States

Vineland, New Jersey 08360, United States

Flushing, New York 11355, United States

Manhasset, New York 10030, United States

New York, New York 10003, United States

New York, New York 10021, United States

New York, New York 10029, United States

Chapel Hill, North Carolina 27599, United States

Charlotte, North Carolina 28203, United States

Durham, North Carolina 27710, United States

Toronto, Ontario M5G 2N2, Canada

Toronto, Ontario M5T 2S8, Canada

Pennsylvania, Hershey, Pennsylvania 17033, United States

Arlington, Texas 76012, United States

Houston, Texas 77030, United States

San Antonio, Texas 78215, United States

Virginia, Fairfax, Virginia 22031, United States

Falls Church, Virginia 22042, United States

Norfolk, Virginia 23502, United States

Richmond, Virginia 23249, United States

Seattle, Washington 98101, United States

Madison, Wisconsin 53715, United States

Madison, Wisconsin 53792, United States

Milwaukee, Wisconsin 53226, United States

Additional Information

Starting date: November 2011
Last updated: May 14, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017